share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

SEC announcement ·  May 25 04:20
Summary by Futu AI
CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.